Repaglinide with Voglibose

Repaglinide with Voglibose is a combination medication used to treat type 2 diabetes mellitus. This combination helps control blood sugar levels by targeting different aspects of glucose metabolism. Below is detailed information on Repaglinide with Voglibose. Repaglinide is an oral hypoglycemic agent that belongs to the meglitinide class. It stimulates the release of insulin from the pancreas, especially after meals. Voglibose, on the other hand, is an alpha-glucosidase inhibitor that slows down the digestion and absorption of carbohydrates in the small intestine. This leads to a reduction in postprandial glucose levels.

Indications

Repaglinide with Voglibose is indicated for the management of type 2 diabetes mellitus in adults.

Dosage

The dosage of Repaglinide with Voglibose should be individualized based on the patient's response and blood glucose levels. Typically, it is taken before meals. A healthcare professional will determine the appropriate dose for each patient.

Contra-Indications

This combination is contraindicated in patients with known hypersensitivity to Repaglinide, Voglibose, or any other components of the formulation. It is also contraindicated in patients with diabetic ketoacidosis.

Special Precautions

-Caution is advised in patients with liver impairment. -Monitoring of renal function is recommended. -The medication should be used with caution in elderly patients. -It is not recommended for use in type 1 diabetes or diabetic ketoacidosis.

Side Effects

Common side effects may include hypoglycemia (especially if meals are skipped), gastrointestinal disturbances (such as abdominal pain, diarrhea), and rash. It's important to report any unusual or severe side effects to a healthcare professional.

Drug Interactions

-Repaglinide with Voglibose may interact with other antidiabetic medications, necessitating adjustments in dosage. -Concomitant use with certain drugs that affect liver enzymes may require careful monitoring.